The centerpiece of Lévy’s reputation is a 1926 paper published in the Revue Neurologique, co-authored with Roussy, under a title that translates as Seven cases of a particular familial disease: gait disturbances, clubfeet and generalized tendon areflexia, with, incidentally, slight clumsiness of the hands. The seven patients, drawn from a single family, displayed a striking and reproducible combination of features. They walked with difficulty, a problem the authors captured in the term dystasia, and they had congenital or early-onset deformities of the feet. Most tellingly, their tendon reflexes were absent throughout, even though the clinical picture was far milder than that of the better-known hereditary ataxia of Friedreich, with which it was immediately compared.

The disorder they described became known as Roussy-Lévy syndrome, and its definition was a triumph of careful phenotyping. At a time when the tools of neurology were the hammer, the tuning fork, the ophthalmoscope and the clinical eye, Lévy and Roussy recognized that a syndrome could be defined by a constellation of signs rather than by any single finding. The combination of areflexia, pes cavus and other foot deformities, distal weakness and an essentially static or slowly progressive course distinguished their patients from those with Friedreich’s ataxia, who typically show pyramidal signs, scoliosis and cardiomyopathy, and from other hereditary neuropathies described in the same era. The 1926 paper stands as an early exercise in what would now be called genotype-phenotype correlation, conducted entirely at the bedside.

Lévy did not stop at description. In 1934, the year of her death, she and Roussy published a follow-up paper on hereditary areflexic dystasia framed as a contribution to the study of the genesis of familial diseases and their kinship with one another. That subtitle matters. The authors were explicitly wrestling with the question of how related clinical entities fit together, whether the syndrome they had described was a disease in its own right, a fruste or abortive form of Friedreich’s ataxia, or part of a broader family of hereditary degenerations. This was a conceptual debate that ran through French neurology of the period, and the 1933 paper by Darré, Mollaret and Landowski, which asked directly whether Roussy-Lévy disease was merely a mild form of Friedreich’s disease using labyrinthine and chronaxie examinations, shows how contested the boundaries remained.

The question was not settled for decades, and the eventual answer vindicated the distinctness of the syndrome in a way neither Lévy nor her contemporaries could have imagined. In 1956, Joseph Lapresle traced and re-examined four of the seven original patients, thirty years after the first publication, confirming the persistence of the phenotype and the remarkable stability of the clinical picture across the decades. Then, in 1973, Lapresle and Salisachs reported a finding that moved the debate from the clinic to the laboratory: a nerve biopsy specimen from one of the original cases of Roussy-Lévy disease showed onion bulb formations, the whorled proliferations of Schwann cell processes that are the pathological signature of a demyelinating and remyelinating hereditary neuropathy. The syndrome was, at its core, a disease of the peripheral nerves.

The molecular coda arrived at the end of the twentieth century. In 1998, Auer-Grumbach and colleagues demonstrated that the Roussy-Lévy syndrome is a phenotypic variant of Charcot-Marie-Tooth disease type 1A, associated with the characteristic duplication on chromosome 17p11.2 that underlies the commonest form of hereditary motor and sensory neuropathy. A year later, Planté-Bordeneuve and colleagues, in a paper pointedly titled The Roussy-Lévy family: from the original description to the gene, closed the loop by studying the descendants of the original kindred and confirming the genetic diagnosis. A clinical picture sketched in 1926 from seven patients and a family tree had been anchored, seventy-three years later, to a specific segment of the human genome.

That trajectory, from bedside description to chromosomal duplication, is precisely why historians of neuroscience find Lévy worth recovering. Her work illustrates how the great nosological debates of interwar neurology, over whether syndromes were separate diseases or variants of one another, were resolved not by better rhetoric but by accumulated follow-up data and, eventually, by molecular genetics. The Roussy-Lévy syndrome is now understood as part of the demyelinating Charcot-Marie-Tooth spectrum, yet its recognition as a distinct phenotype in 1926 helped clinicians for decades to counsel families, predict prognosis and distinguish patients whose disease would remain relatively static from those facing the progressive disability of Friedreich’s ataxia.

Lévy’s scientific range extended beyond hereditary neuropathy. In 1925 she published a monograph on the late manifestations of epidemic encephalitis, the prolonged and delayed forms of the disease that swept Europe in the wake of the First World War and left many patients with parkinsonian and other sequelae years after the acute infection. The work places her among the clinicians who grappled with encephalitis lethargica, one of the great unsolved puzzles of the era, and shows a career that engaged with both the degenerative and the infectious frontiers of neurology. Contemporaries remembered her within the vibrant Parisian school that included figures such as Jean Lhermitte, and the historical literature, notably Peter Koehler’s 2018 study of Lévy and the Roussy-Lévy syndrome in the Journal of the History of the Neurosciences, has begun to piece together the details of her short but productive career.

Her early death in 1934, at the age of forty-eight, cut short a career that had already produced two landmark papers on hereditary areflexic dystasia and a substantial monograph on post-encephalitic disease. It also helps explain why her name faded. Eponyms tend to attach to those who survive to promote, extend and defend their syndromes, and Lévy had no such opportunity. The new biographical account, written by Carlos Alvarado-De la Hoz, Andres Felipe Cardenas-Cruz and Alba Lucia Marentes-Cubillos, neurologists at the Hospital Universitario San Ignacio and the Pontificia Universidad Javeriana in Bogotá, forms part of a deliberate effort by the Journal of Neurology to document the pioneers whose contributions underpin modern practice, and it appeared in volume 273 of the journal as article number 601.

For a modern readership, the story carries a broader lesson about how medicine accumulates knowledge. The seven patients described in 1926 were examined with none of the instruments that would eventually explain their condition, yet the precision of the original observation was good enough that a biopsy in 1973 and a gene study in 1999 could be anchored to those very cases. Clinical description, often dismissed as the antiquarian wing of neuroscience, proved to be durable data. Gabrielle Lévy’s legacy is a reminder that the careful documentation of a single family, done well, can outlast the career and even the life of the observer, and that some of the most consequential figures in the history of the neurosciences are those whose names survive only in the hyphen of a syndrome they never lived to see explained.

Subject of Research: Historical biography of neurologist Gabrielle Lévy and the Roussy-Lévy syndrome

Article Title: Gabrielle Lévy (1886–1934)

Article References: Alvarado-De la Hoz, C., Cardenas-Cruz, A. F., & Marentes-Cubillos, A. L. (2026). Gabrielle Lévy (1886–1934). Journal of Neurology, 273(10), Article 601. https://doi.org/10.1007/s00415-026-14135-y

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14135-y

Keywords: Gabrielle Lévy, Roussy-Lévy syndrome, hereditary areflexic dystasia, Charcot-Marie-Tooth disease, Friedreich's ataxia, neurology history, hereditary neuropathy, peripheral nerve, genetics, Pioneers in Neurology, Journal of Neurology, medical eponyms

The most widely cited monument to Yahr’s career is the 1967 paper he co-authored with Margaret Hoehn, titled Parkinsonism: Onset, Progression and Mortality, published in the journal Neurology. That paper introduced what became known as the Hoehn and Yahr scale, a five-stage classification of Parkinson’s disease severity based on the degree of functional impairment. Stage one describes unilateral involvement, typically with minimal or no functional impairment; stage two marks bilateral disease without impairment of balance; stage three adds postural instability, producing mild to moderate functional disability while the patient remains physically independent; stage four denotes severe disability, with the patient still able to walk or stand unassisted; and stage five describes the wheelchair-bound or bedridden state unless aid is constantly provided. The elegance of the system lay in its simplicity: a bedside observation, requiring no instrumentation, that captured the trajectory of the illness in a single ordinal number.

The technical rationale behind the scale reflected the clinical realities of the pre-levodopa era. Hoehn and Yahr analyzed a large cohort of patients with parkinsonism, documenting the natural history of onset, the pattern of symptom progression, and mortality relative to the general population. Their data demonstrated that disability accumulated in a broadly predictable sequence, beginning asymmetrically and progressing to bilateral involvement, and that mortality in parkinsonian patients was significantly elevated compared with matched controls. By anchoring disease severity to observable motor signs rather than subjective impressions, the scale provided the first widely reproducible endpoint for clinical research. More than five decades later, modified versions of the scale remain embedded in the Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale and in the regulatory frameworks used to approve new Parkinson’s therapies.

Yahr’s second great contribution was his role in bringing levodopa into mainstream clinical practice. The pharmacological groundwork had been laid by others: Arvid Carlsson had established dopamine as a neurotransmitter in the brain and shown that reserpine-induced parkinsonism in animals could be reversed by levodopa, work that later earned him a Nobel Prize; Oleh Hornykiewicz had demonstrated that dopamine concentrations were profoundly depleted in the striata of deceased Parkinson’s patients; and George Cotzias had pioneered high-dose oral levodopa regimens. A 2015 review in Movement Disorders by Andrew Lees, Eduardo Tolosa and C. Warren Olanow grouped Yahr alongside Carlsson, Hornykiewicz and Cotzias as the four pioneers of levodopa treatment, a designation that underscores how central he was to translating laboratory dopamine biology into bedside therapy.

The decisive clinical paper came in 1969, when Yahr, together with Roger Duvoisin, M. J. Schear, R. E. Barrett and Margaret Hoehn, published Treatment of Parkinsonism with Levodopa in the Archives of Neurology. The study reported the results of levodopa administration in a substantial series of parkinsonian patients and documented striking improvements in the cardinal motor features of the disease, including bradykinesia, rigidity and tremor. The paper was among the first large, systematically documented demonstrations, conducted at a major American academic center, that restoring dopaminergic tone could produce clinically meaningful benefit in Parkinson’s disease. Its publication helped catalyze the rapid adoption of levodopa, often combined with a peripheral dopa-decarboxylase inhibitor to reduce nausea and cardiovascular side effects, as the standard of care, a position the drug still holds as the most effective symptomatic treatment available.

The impact of that therapeutic shift is difficult to overstate. Before levodopa, a diagnosis of Parkinson’s disease carried a grim prognosis; Hoehn and Yahr’s own 1967 mortality data showed that patients died at markedly elevated rates compared with the general population, often after years of progressive immobility, aspiration and institutionalization. After levodopa, life expectancy and quality of life improved substantially, and the management of the disease shifted from palliative custodial care to long-term pharmacological treatment with attention to motor complications such as wearing-off and dyskinesia. The 1998 reprint of the Hoehn and Yahr paper in Neurology, appearing in a series honoring classic papers, attested to the enduring relevance of the original work even as the therapeutic landscape it helped create had transformed the disease course it once described.

The new biographical article also situates Yahr within the institutional history of American neurology. He spent the core of his career in New York, where he built one of the leading movement disorders programs of his era and trained generations of neurologists who went on to shape the field. His department became a proving ground for systematic clinical investigation in parkinsonism, combining careful bedside phenomenology with emerging quantitative methods and the first generation of controlled therapeutic trials. The tribute’s authors, based at the Federal University of Paraná and the Federal University of Paraíba in Brazil, are themselves movement disorders specialists, and their article forms part of a broader historiographical effort to preserve the intellectual genealogy of a subspecialty that only consolidated as a distinct field in the second half of the twentieth century.

Contemporaries marked Yahr’s passing in 2004 with obituaries and tributes in the leading medical journals. The British Medical Journal published an obituary by F. Charatan, and the Journal of Neural Transmission carried a tribute by Peter Riederer, Emmanuel Hirsch, Moussa Youdim and Donald Calne, honoring his scientific achievements and his personal influence on colleagues across three continents. Such coordinated commemoration reflected the breadth of his network: Yahr’s collaborators and trainees populated departments of neurology throughout the United States and beyond, and his editorial work and society leadership helped professionalize the study of movement disorders at a time when the field was transitioning from descriptive neurology to mechanism-driven neuroscience.

From a modern vantage point, the methodological contributions of the Hoehn and Yahr era reveal both their power and their limits. The original scale is a rating of motor disability, insensitive to the non-motor dimensions of Parkinson’s disease, including autonomic dysfunction, cognitive decline, sleep disturbance and neuropsychiatric symptoms, which contemporary research has moved to the center of the field. Modern clinical trials increasingly rely on continuous digital monitoring, biomarkers such as alpha-synuclein seed amplification assays, and composite endpoints that capture disease heterogeneity far beyond a five-stage ordinal ranking. Yet the conceptual move that Hoehn and Yahr made, namely that Parkinson’s disease must be measured against its natural history with standardized, reproducible instruments, remains the epistemological foundation on which all subsequent scales, from the UPDRS to the MDS criteria for prodromal and diagnosed disease, were built.

The story of Melvin Yahr is ultimately a story about the speed at which clinical neuroscience can change when rigorous observation meets a mechanistic breakthrough. Within roughly a decade of Carlsson’s dopamine experiments, a dopamine precursor was in routine clinical use, and within the same decade a severity scale had been devised that made the disease legible to science. The Journal of Neurology’s decision to devote a Pioneers in Neurology article to Yahr, published in 2026, more than two decades after his death, testifies to how completely his twin legacies, the staging of Parkinson’s disease and the levodopa revolution, have been absorbed into the everyday grammar of neurology. Every clinician who assigns a patient a Hoehn and Yahr stage, and every patient who takes a levodopa tablet, is exercising a legacy forged in the New York clinics of the 1960s by a physician who insisted that parkinsonism be measured, quantified and treated.

Subject of Research: Historical biography of neurologist Melvin Yahr and his contributions to Parkinson's disease staging and levodopa treatment

Article Title: Melvin Yahr (1917–2004)

Article References: Teive, H. A. G., Coutinho, L., Meira, A. T., & Camargo, C. H. F. (2026). Melvin Yahr (1917–2004). Journal of Neurology, 273(10), Article 637. https://doi.org/10.1007/s00415-026-14184-3

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14184-3

Keywords: Melvin Yahr, Parkinson's disease, Hoehn and Yahr scale, levodopa, movement disorders, neurology history, dopamine, clinical staging, Journal of Neurology, biographical research, basal ganglia, pioneers in neurology

Wood’s early life unfolded in a Philadelphia that was rapidly becoming the scientific capital of the United States. Born in 1841, he came of age at a time when American medicine was still largely an apprenticeship trade, taught at the bedside rather than in the laboratory. Yet Wood’s generation would transform that landscape, importing the experimental methods of European physiology and pharmacology and building the first university departments devoted to the scientific study of disease. Wood himself would later recount these formative years in his Reminiscences of an American Pioneer in Experimental Medicine, delivered before the College of Physicians of Philadelphia in 1920, near the end of his life. That memoir remains one of the most valuable first-hand accounts of what it took to establish experimental medicine in nineteenth-century America, and it anchors much of the modern scholarship on his career, including the biographical memoir prepared for the National Academy of Sciences by George B. Roth in 1959.

The scale of Wood’s ambitions becomes clearer when one considers the breadth of his appointments. In an era when most physicians confined themselves to a single specialty, Wood held professorships in nervous diseases, in pharmacology and therapeutics, and in general medicine, moving fluidly among fields that today would be considered separate careers. This versatility reflected both his temperament and the state of nineteenth-century science, in which the boundaries between physiology, pharmacology, and clinical medicine were still porous. His work in pharmacology contributed to the emerging science of drug action, while his clinical teaching brought rigorous diagnostic methods to the study of disorders of the nervous system. The University of Pennsylvania’s departmental archives, which trace the history of its neurology chair from 1871 onward, credit Wood with establishing the institution’s first professorship and chair of neurology, a milestone documented in the broader scholarly literature on early American professorships in neurology by Christopher Goetz and E.J. Pappert.

Wood’s most enduring contribution to the neurological literature came in 1887 with the publication of Nervous Diseases and Their Diagnosis, a treatise issued by the J. B. Lippincott Company of Philadelphia. The book’s subtitle reveals its ambitions: a treatment of the phenomena produced by diseases of the nervous system, with especial reference to the recognition of their causes. At a time when American practitioners relied heavily on European texts, Wood’s treatise represented an effort to systematize neurological diagnosis for an American audience, organizing clinical phenomena according to the underlying lesions and etiologies that produced them. The work placed emphasis on the logical pathway from observed symptoms to anatomical and causal explanations, a mode of reasoning that would become the backbone of clinical neurology as the specialty matured in the twentieth century. Modern historians of movement disorders continue to cite Wood’s clinical descriptions; his observations are referenced in the literature on Meige syndrome, the adult-onset cranial dystonia characterized by blepharospasm and orofacial movements, as scholars such as Mark S. LeDoux and later Pandey and Sharma have traced in the pages of Parkinsonism and Related Disorders and the Journal of the Neurological Sciences.

Wood’s career also intersected with the professional organization that would come to define American neurology. He was a member of the American Neurological Association, founded in 1875, and his name appears in the association’s semi-centennial volume of 1924, where Isaac Abrahamson and T.H. Weisenburg compiled the biographical records of past and present members along with the association’s military history. That membership placed Wood among the small cohort of physicians who, in the closing decades of the nineteenth century, worked to give neurology an institutional identity in the United States, complete with its own societies, journals, and academic chairs. The Goetz and Pappert survey of early American professorships in neurology, published in Annals of Neurology in 1996, situates Wood’s Pennsylvania chair within this wider movement, in which a handful of universities competed to formalize the teaching of nervous diseases.

Beyond his scientific work, Wood left an unexpected mark on the history of American art. He was the subject of a portrait by Thomas Eakins, the great Philadelphia realist painter whose unsparing depictions of surgeons and scientists documented the medical world of his city. Eakins painted several members of the Philadelphia medical establishment, and his portrait of Wood is discussed in the Bulletin of the Detroit Institute of Arts, which holds the work. The painting captures the convergence of art and medicine that characterized Gilded Age Philadelphia, a city where the Pennsylvania Academy of the Fine Arts and the College of Physicians drew from the same social world. For historians, such portraits serve as visual documents of the professional self-image that physicians like Wood cultivated: sober, exacting, and unmistakably modern.

The retrospective on Wood also invites reflection on how the discipline he helped found has changed. When Wood took up his chair in 1871, neurology lacked the electrophysiological, imaging, and molecular tools that define the field today. Diagnosis rested on careful history-taking and physical examination, on the correlation of clinical signs with post-mortem findings, and on the classification of syndromes that could be recognized at the bedside. Wood’s 1887 treatise embodies that approach, and its emphasis on the recognition of causes anticipates the etiological thinking that drives contemporary neurology, even as the technologies of investigation have been transformed beyond anything a nineteenth-century practitioner could have imagined. The continuity, historians argue, lies less in the instruments than in the intellectual discipline of localizing and explaining disease.

Wood’s longevity itself is notable. He lived to 1920, long enough to see neurology acquire laboratory foundations, to witness the rise of bacteriology and the transformation of pharmacology into an experimental science, and to record his memories of the pioneering era in the memoir delivered to the College of Physicians of Philadelphia. Published in the third series of the college’s transactions, the Reminiscences run to more than sixty pages and are now freely accessible through the Internet Archive, allowing a new generation of readers to hear the voice of a man who helped build American experimental medicine from the ground up. The document is prized not only for its factual content but for its window into the culture of nineteenth-century Philadelphia science, its rivalries, its institutions, and its sense of possibility.

Triarhou’s profile, received by the journal in August 2026 and published on 23 September 2026 in volume 273 of the Journal of Neurology, draws on these primary and secondary sources to restore Wood to the prominence he once held. The piece forms part of a series that has documented the lives of the founders of neuroscience across Europe and the Americas, and it situates Wood alongside the other figures whose names are attached to the discipline’s early chairs and societies. The author, who works at the interface of psychology, brain science, and the history of neuroscience, has made a career of such biographical reconstructions, and the Wood article follows the series’ format of combining archival evidence with an assessment of the subject’s scientific contributions.

For modern readers, the story of Horatio C. Wood is a reminder that the institutions of medicine are not timeless but were built, chair by chair and treatise by treatise, by individuals with the energy to imagine them. The first professor of neurology at Penn, the author of a foundational American text on nervous diseases, a pharmacologist, a physician, and a sitter for Thomas Eakins, Wood embodied an era when a single career could span the whole of medical science. His portrait now hangs in the Detroit Institute of Arts; his memoir survives online; his treatise is cited in the histories of dystonia; and his chair, established in 1871, continues as part of one of the leading neurology departments in the United States. Few pioneers leave so many traces across so many fields, and the new profile in the Journal of Neurology ensures that this Philadelphia polymath will not be forgotten by the specialty he helped to create.

Subject of Research: Historical profile of Horatio C. Wood, pioneer of American neurology

Article Title: Horatio C. Wood (1841–1920)

Article References: Triarhou, L. C. (2026). Horatio C. Wood (1841–1920). Journal of Neurology, 273(10), Article 615. https://doi.org/10.1007/s00415-026-14129-w

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14129-w

Keywords: Horatio C. Wood, neurology history, University of Pennsylvania, Journal of Neurology, Pioneers in Neurology, nervous diseases, pharmacology, Thomas Eakins, American Neurological Association, medical history, Meige syndrome, Philadelphia

Weisenburg’s most cited early achievement came in 1910, when he published in the Journal of the American Medical Association a detailed case report of a cerebello-pontile tumor that had been misdiagnosed for six years as tic douloureux, the severe facial pain syndrome now more commonly called trigeminal neuralgia. The case was remarkable not only for its diagnostic detective work but for its systematic description of irritation symptoms affecting the ninth and twelfth cranial nerves, the glossopharyngeal and hypoglossal. By carefully correlating the patient’s paroxysmal pain in the throat and tongue regions with the anatomical course of these nerves, Weisenburg effectively provided one of the earliest clinical characterizations of glossopharyngeal neuralgia, an entity that later reviewers would trace directly back to his report. The lesson he drew, that structural lesions of the posterior fossa can masquerade for years as functional pain syndromes, remains embedded in modern differential diagnosis.

That paper illustrated a methodological habit that defined Weisenburg’s entire career: an insistence that clinical observation be anchored in meticulous anatomical correlation and, wherever possible, quantitative comparison. His interest in localization did not stop at the cranial nerves. In 1927 he contributed to a symposium on the cerebellum in the journal Brain, presenting an extended analysis of cerebellar localization and its symptomatology. At a time when the cerebellum was still often treated as a black box concerned vaguely with coordination, Weisenburg synthesized the available physiological and pathological evidence to argue for a more differentiated map of cerebellar function, connecting specific symptom complexes to specific cerebellar regions. The symposium paper became a reference point for subsequent work on cerebellar signs, including the subtleties of dyssynergia, dysmetria and the variability of clinical expression in cerebellar disease.

Yet it is in the study of aphasia, the devastating loss or impairment of language following brain injury, that Weisenburg made his most enduring scientific mark. In the late 1920s and early 1930s he directed an ambitious research program on language disorders, culminating in the Charles K. Mills memorial lecture delivered before the Philadelphia Neurological Society and published in 1934 in the Archives of Neurology and Psychiatry under the title A Study of Aphasia. The lecture was not a single case report but a synthesis of a large, systematically assembled series of aphasic patients, examined with a battery of tests that Weisenburg and his collaborators designed to probe language function along multiple dimensions: comprehension, repetition, naming, reading and writing. He had presented an early version of this testing framework at the First International Neurological Congress in Berne in 1931, where he also reported on the status of neurology in the United States, signaling his dual commitment to research infrastructure and scientific measurement.

What made the aphasia work genuinely innovative was its insistence on the study of normals. In a 1929 paper in the Journal of the American Medical Association, Weisenburg argued that no account of pathological language could be interpreted correctly without a rigorous description of normal variation in linguistic and intellectual ability across the healthy population. This was a strikingly modern methodological position, decades before the formalization of standardized neuropsychological norms. His group tested control subjects on the same instruments applied to aphasic patients, allowing deficits to be measured against the actual distribution of intact performance rather than against idealized expectations. Contemporary historians of neuropsychology have noted that this concern with defining the normal baseline, and the methodological puzzles it raised about intelligence testing in brain-damaged populations, anticipated debates that continue in the literature on aphasia assessment to this day.

The Mills memorial lecture, published in the opening issue of the Archives of Neurology and Psychiatry for 1934, condensed this program into thirty-three pages that ran counter to the rigid classification schemes then dominant in aphasiology. Weisenburg emphasized the heterogeneity of aphasic syndromes and the partial dissociations among language modalities, resisting the temptation to force every patient into a small number of canonical categories. His quantitative, multi-dimensional approach foreshadowed the psychometric tradition that would later flourish in mid-century neuropsychology, and his collaborators carried the framework forward after his death. In an era when much of aphasiology was fought out between anatomical reductionists and holistic skeptics, Weisenburg’s data-driven middle path proved remarkably prescient.

Weisenburg was also a builder of institutions. He served as editor of the Archives of Neurology and Psychiatry, one of the leading neurological journals in the English-speaking world, shaping the publication record of American neurology during a period of rapid growth. A poignant artifact of that role survives in the Wilder Penfield Digital Collection at McGill: a letter typed on Archives of Neurology and Psychiatry publication office letterhead, dated February 20, 1934, addressed to Wilder Penfield, the pioneering neurosurgeon then transforming the surgical treatment of epilepsy in Montreal. The letter, written just months before Weisenburg’s death, captures the network of correspondence through which the leading neurologists and neurosurgeons of the era exchanged findings, manuscripts and professional judgments. Triarhou’s profile uses such archival traces to situate Weisenburg not as an isolated genius but as a node in a dense transatlantic scientific community that included Penfield, Tilney, McConnell and the heirs of Charles K. Mills.

The circumstances of his death at fifty-eight prompted immediate tributes from colleagues. Frederick Tilney, the Columbia neurologist and himself a distinguished scholar, authored an obituary in the Archives of Neurology and Psychiatry spanning pages 842 to 849 of volume 32, a length that testifies to the esteem in which Weisenburg was held. James McConnell published a parallel memorial in the Journal of Nervous and Mental Disease. Both accounts portray a clinician of unusual diagnostic acuity, a demanding but generous teacher and a researcher who elevated the evidentiary standards of his specialty. Their combined testimony, mined anew by Triarhou, offers modern readers a portrait of what academic neurology looked like in the United States between the world wars: small departments, personal correspondence networks, journals that doubled as scientific forums and a growing awareness that neurology needed its own rigorous psychology.

The reappraisal of Weisenburg’s career comes at a moment when several of his themes have returned to prominence. The study of healthy control populations as an essential complement to patient research, the multidimensional assessment of language, and the careful anatomical dissection of cranial nerve syndromes are all live issues in contemporary neuroscience and neurology. Glossopharyngeal neuralgia, first given clinical definition in his 1910 report, is now routinely treated with microvascular decompression procedures of the kind Penfield’s generation helped to pioneer. Aphasia testing, descendants of whose logic appear in modern standardized batteries, remains central to stroke rehabilitation. And the cerebellum, whose functional organization Weisenburg helped to clarify, has re-emerged as a major focus of research into cognition as well as movement. Triarhou’s profile, published as volume 273, article number 614 of the Journal of Neurology, thus does more than commemorate an anniversary; it demonstrates how the methodological instincts of an early twentieth-century clinician, his demand for baselines, his suspicion of tidy categories and his fusion of bedside observation with quantitative test data, continue to define good practice nearly a century later.

Subject of Research: Historical profile of neurologist Theodore H. Weisenburg and his contributions to aphasia research, cerebellar symptomatology and cranial nerve pain syndromes

Article Title: Theodore H. Weisenburg (1876–1934)

Article References: Triarhou, L. C. (2026). Theodore H. Weisenburg (1876–1934). Journal of Neurology, 273(10), Article 614. https://doi.org/10.1007/s00415-026-14120-5

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14120-5

Keywords: Theodore H. Weisenburg, aphasia, neurology history, glossopharyngeal neuralgia, cerebellar localization, cranial nerves, neuropsychology, Journal of Neurology, Lazaros C. Triarhou, Charles K. Mills memorial lecture, Archives of Neurology and Psychiatry, pioneers in neurology

Mills was born in 1845 and came of age at a moment when the study of the nervous system was undergoing a profound conceptual revolution. The doctrine of cerebral localization, championed in Europe by figures such as Paul Broca and John Hughlings Jackson, was steadily overturning the older view of the brain as an undifferentiated organ. American medicine, however, lagged behind its European counterparts in embracing these ideas, and it fell to a small group of Philadelphia clinicians to translate localization theory into bedside practice. Mills emerged as one of the most forceful American advocates of this new way of thinking, arguing that careful correlation of symptoms with lesions could yield practical guidance for diagnosis and even for surgery.

His early scholarly output reflected this commitment. In 1879, barely into his thirties, Mills published notes on the localization of diseases of the brain, an early demonstration of his conviction that neurology had to be grounded in anatomical precision. He would expand on this theme throughout his career, culminating in his 1889 address on cerebral localization in its practical relations, delivered before the First Triennial Session of the Congress of American Physicians and Surgeons in Washington, DC. That expansive paper, running to a hundred printed pages, laid out the state of the art in localization and argued that the doctrine was not merely an academic curiosity but a working tool for the practicing physician.

Mills was also a clinician-surgeon in an era when operating on the brain was still a daring proposition. In 1891, together with W. W. Keen Jr., one of America’s pioneering surgeons, he reported a landmark case of Jacksonian epilepsy in which trephining was performed, a small tumor was removed, and epileptogenic cortex was excised. The case exemplified the translational power of localization theory: by mapping a patient’s seizures to a specific cortical region, the team could justify an operation that would have been unthinkable under earlier frameworks. Such collaborations between neurologists and surgeons helped establish the intellectual foundations on which modern neurosurgery would later be built.

Perhaps no area of Mills’s work has proven more durable than his contributions to aphasiology. In 1904 he published a substantial treatise in the Journal of the American Medical Association on the treatment of aphasia by training, a remarkably forward-looking document that anticipated modern rehabilitation approaches to language disorders. At a time when aphasia was largely regarded as a fixed deficit to be described and classified, Mills argued that systematic training could produce meaningful recovery in patients with language impairment. His emphasis on therapeutic intervention, rather than passive description, placed him decades ahead of the formal development of speech-language pathology and resonates strongly with contemporary principles of neuroplasticity and rehabilitation medicine.

Mills’s name also survives in the eponymous Mills’ syndrome, a rare clinical entity characterized by progressive ascending hemiplegia without sensory disturbance or dementia. The syndrome has enjoyed a genuine scientific afterlife: a 2019 study in the Journal of Neurology revisited Mills’ syndrome in the light of modern neuroimaging and genetics, examining whether the historical description corresponds to recognizable disease entities such as primary lateral sclerosis or hereditary spastic paraplegia variants. That a clinical picture first delineated in the nineteenth century could prompt a comprehensive re-evaluation in the twenty-first speaks to the descriptive precision that Mills and his contemporaries brought to the neurological examination.

Beyond his individual discoveries, Mills played a crucial institutional role in the professionalization of American neurology. He was a leading figure in the American Neurological Association, and his bibliography, published in the association’s semi-centennial anniversary volume of 1924, documented a scholarly output of extraordinary breadth spanning neuroanatomy, clinical neurology, psychiatry, and medical history. He was among the physicians who recognized that neurologic specialization in America depended not only on clinical skill but on technology, a thesis later explored by historian Douglas Lanska in a 1997 analysis of the role of technology in neurologic specialization. The adoption of instruments and laboratory methods, Lanska argued, helped carve neurology out of general medicine, and Mills was an active participant in that transformation.

Contemporaries remembered Mills as a commanding teacher and a meticulous clinician. Two obituary notices published in 1931, the year of his death, capture the esteem in which he was held. Smith Ely Jelliffe, writing in the Journal of Nervous and Mental Disease, and T. H. Weisenburg, writing in the Archives of Neurology and Psychiatry, both offered appreciations of a man who had spent more than half a century shaping the specialty. Weisenburg’s extended memorial, running to nine pages, surveyed the full range of Mills’s contributions, from cerebral localization and epilepsy surgery to aphasia therapy and the history of medicine. Later generations of scholars, including David Goldblatt and James Kennedy in a 1983 essay in Seminars in Neurology, returned to Mills under the evocative title The all-important matter, underscoring how central his work remained to understanding the development of American neurology.

The new profile by Triarhou appears in the Journal of Neurology as part of its long-running Pioneers in Neurology series, which commemorates the figures whose insights built the modern discipline. Placing Mills in this company is fitting. He practiced at the hinge point between the era of heroic gross localization and the era of laboratory neuroscience, and he understood better than most of his contemporaries that the two had to be joined. His insistence that localization be practical, that therapy be attempted even when prognosis seemed bleak, and that the specialty document its own history gave American neurology a template it still follows. As modern neurology grapples with new questions about brain mapping, rehabilitation, and the integration of technology into clinical practice, the career of Charles K. Mills offers a reminder that these concerns are not new but represent the continuing unfolding of an agenda set more than a century ago by physicians who worked with little more than a hammer, a reflex hammer, and an exacting eye at the bedside.

Subject of Research: Historical profile of neurologist Charles K. Mills (1845–1931) and his pioneering contributions to cerebral localization and American neurology.

Article Title: Charles K. Mills (1845–1931)

Article References: Triarhou, L. C. (2026). Charles K. Mills (1845–1931). Journal of Neurology, 273(10), Article 613. https://doi.org/10.1007/s00415-026-14114-3

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14114-3

Keywords: Charles K. Mills, history of neurology, cerebral localization, aphasia, Mills' syndrome, Jacksonian epilepsy, American Neurological Association, Philadelphia neurology, pioneers in neurology, neurological history, Charles, Mills